Apogenix biomarker pinpoints responders to glioblastoma drug
By Cormac Sheridan
Staff Writer
Staff Writer
Monday, January 13, 2014
Apogenix GmbH is meeting officials from three of Europe’s leading national drug regulators in the coming weeks to evaluate whether they will support a bid to obtain conditional marketing approval for its glioblastoma drug APG101, following a fresh biomarker analysis, which shows that the therapy offers likely responders a 10-month survival benefit. The Heidelberg, Germany-based firm unveiled the new analysis at the J.P. Morgan Healthcare Conference in San Francisco, where it is drumming up interest from investors and potential partners alike.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.